Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers M > Headlines for MedImmune, Inc. > News item |
MedImmune at neutral by Merrill
MedImmune Inc. was rated by Merrill Lynch analyst Eric Ende at neutral after the company delivered "disappointing" data from the phase 3 study comparing Numax to Synagis. The analyst doesn't believe the company will be able to charge a premium for Numax in addition to the reimbursement issue. In the end, Merrill does not believe Numax will be able to expand the Synagis franchise. Shares of the Gaithersburg, Md.-based biotechnology company were up 80 cents, or 2.53%, at $32.38. (Nasdaq: MEDI)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.